Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis
Results support progression of EMERALD clinical trial of Resolution’s engineered macrophage therapy, RTX001
- Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in the journal Cell Stem Cell
- Resolution is pioneering engineered Regenerative Macrophage Therapy – which uses engineered macrophages designed to deliver a more potent and durable clinical effect, to treat a more severe patient population with high unmet clinical needs
- Interim data from Resolution’s Phase I/II EMERALD study of RTX001, its engineered RMT for patients with end-stage liver disease, is expected in the second half of 2026
Edinburgh and London, UK, 25 May 2026 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering engineered Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today welcomes the publication of positive four-year follow-up data from the University of Edinburgh’s MATCH trial of RMT in patients with liver cirrhosis, in the journal Cell Stem Cell.
